Requesting asciminib for serious illness when no other options remain
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This program lets doctors request an unapproved drug for patients with serious, life-threatening diseases when no other good options exist. It's a way to get the medicine outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening illness and no other good treatment options left.
- Your doctor must ask the drug company for this medicine for you.
- You can't join a clinical trial, or you are already in one and can't keep going.
- The possible benefits of this treatment should outweigh the risks for you.
- This treatment must be allowed by your country's laws and rules.
- Your doctor must meet any extra medical requirements set by the company or your local health authority.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
Hear when a new Chronic Myeloid Leukemia in Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.